Printer Friendly

IMMUNOMEDICS REPORTS INITIAL CLINICAL RESULTS OF A NEW CANCER THERAPEUTIC; ANTIBODY HUMANIZATION PROGRAM ALSO ADVANCES

 IMMUNOMEDICS REPORTS INITIAL CLINICAL RESULTS OF A NEW CANCER
 THERAPEUTIC; ANTIBODY HUMANIZATION PROGRAM ALSO ADVANCES
 WARREN, N.J., May 22 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU), reported today, at the annual meeting of the American Association for Cancer Research, in San Diego, the promising clinical trial results of the company's second-generation, high-affinity antibody (MN-14) that targets carcinoembryonic antigen (CEA).
 This anti-CEA antibody detected 64 of the 72 tumors previously found by CT-scanning; 43 additional tumor sites were also disclosed by MN-14 antibody scanning in 22 patients with colorectal cancer, who were treated with this radioactive antibody (I-131) in a Phase I/II trial. This product, covered by European, Canadian, and U.S. patents, may be useful in a large number of patients because CEA is present in a wide variety of cancers, including some patients with lung, colorectal, breast, ovarian and cervical cancers.
 "The MN-14 antibody may be especially useful in treating CEA- producing cancers because of its high-binding property. This antibody is scheduled to be used, labeled with Rhenium-188, in other cancer therapy clinical trials to begin by the end of 1992," noted Carl Pinsky, vice president, medical affairs.
 "The company is currently in the process of 'humanizing' MN-14 in order to reduce the immunogenic response (allergic reaction) which may occur when using a mouse antibody. Antibody humanization involves splicing certain components of a mouse antibody to a human antibody, by recombinant DNA methods, thus reducing the mouse portions. Immunomedics is making progress in its antibody humanization efforts. A paper on this research progress was also presented at this cancer meeting," stated Hans Hansen, vice president, exploratory research.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases.
 -0- 5/22/92
 /CONTACT: Amy Factor of Immunomedics, 908-647-5400/
 (IMMU) CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU:


GK-OS -- NY002 -- 3186 05/22/92 09:16 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 22, 1992
Words:352
Previous Article:NATIONAL INTERGROUP REDEEMS PREFERRED SHARE PURCHASE RIGHTS; BOARD ALSO ANNOUNCES PREFERRED DIVIDEND, ANNUAL MEETING SCHEDULE
Next Article:NATIONAL COMPUTER SYSTEMS ANNOUNCES QUARTERLY CASH DIVIDEND
Topics:


Related Articles
IMMUNOMEDICS AWARDED PATENT FOR IMAGING AND THERAPEUTIC AGENTS
IMMUNOMEDICS PURSUES NEW CANCER THERAPY; PATENT ALLOWED FOR METHOD COMBINING CYTOKINES AND RADIOACTIVE ANTIBODIES
IMMUNOMEDICS REPORTS PROMISING LYMPHOMA THERAPY RESULTS; CLINICAL FINDINGS PRESENTED AT ANNUAL NUCLEAR MEDICINE MEETING
IMMUNOMEDICS REPORTS ON LYMPHOMA IMAGING AND THERAPY PROGRESS AT CANCER CONFERENCE
IMMUNOMEDICS GRANTED THREE PATENTS IN JAPAN
IMMUNOMEDICS MAKES ADVANCES IN ANTIBODY RECONSTRUCTION AND HUMANIZATION; PROGRESS IN CANCER THERAPY PROGRAMS REPORTED
Immunomedics Awarded U.S. Patent for Therapeutic Conjugates of Toxins and Drugs
Immunomedics patents new '2-Punch' therapy of cancer with bispecific fusion proteins.
Medix licenses Immunomedics' carcinoembryonic antigen technology.
Immunomedics obtains lymphoma antibody patent.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters